Nova Mentis Life Science (XCNQ:NOVA) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Nova Mentis Life Science ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nova Mentis Life Science's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

Nova Mentis Life Science ROCE % Historical Data

The historical data trend for Nova Mentis Life Science's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science ROCE % Chart

Nova Mentis Life Science Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-69.09

-18.10

-40.39

-187.96

-773.25

Nova Mentis Life Science Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Mar24
ROCE %	Get a 7-Day Free Trial															-170.49	-345.55	-	-	-

Nova Mentis Life Science ROCE % Calculation

Nova Mentis Life Science's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-1.937	/	( ( (0.881 - 0.422)	+	(0.297 - 0.255) )	/ 2 )
	=	-1.937	/	( (0.459	+	0.042)	/ 2 )
	=	-1.937	/	0.2505
	=	-773.25 %

Nova Mentis Life Science's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	-0.584	/	( ( (0.054 - 0.655)	+	(0.04 - 0.995) )	/ 2 )
	=	-0.584	/	( ( -0.601	+	-0.955 )	/ 2 )
	=	-0.584	/	-0.778
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Nova Mentis Life Science (XCNQ:NOVA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nova Mentis Life Science ROCE % Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Mentis Life Science (XCNQ:NOVA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (XCNQ:NOVA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NMLSF:USA HN3Q:Germany

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Executives

Derek Lloyd Harry Ivany

10% Security Holder, Director, Senior Officer